Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
R21 NS098169
NINDS NIH HHS - United States
PubMed
27923871
PubMed Central
PMC5282956
DOI
10.1194/jlr.m072751
PII: S0022-2275(20)31421-8
Knihovny.cz E-zdroje
- Klíčová slova
- brain atrophy, cholesterol, magnetic resonance imaging,
- MeSH
- cholesterol krev MeSH
- degenerace nervu krev diagnostické zobrazování farmakoterapie patologie MeSH
- demyelinizační nemoci krev diagnostické zobrazování farmakoterapie patologie MeSH
- dospělí MeSH
- HDL-cholesterol krev MeSH
- interferon beta 1a aplikace a dávkování MeSH
- LDL-cholesterol krev MeSH
- lidé MeSH
- lipidy krev MeSH
- magnetická rezonanční tomografie MeSH
- mozek diagnostické zobrazování účinky léků patofyziologie MeSH
- roztroušená skleróza krev diagnostické zobrazování farmakoterapie patologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Názvy látek
- cholesterol MeSH
- HDL-cholesterol MeSH
- interferon beta 1a MeSH
- LDL-cholesterol MeSH
- lipidy MeSH
The purpose of this work was to determine whether changes in cholesterol profiles after interferon-β (IFN-β)1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 ± 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-β1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-β1a initiation (all P < 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-β1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P < 0.001), percent gray matter volume change (P < 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-β1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.
Department of Pharmaceutical Sciences State University of New York Buffalo NY
Department of Statistics and Probability University of Economics Prague Czech Republic
Zobrazit více v PubMed
1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 43: 655–661. PubMed
Yong V. W., Chabot S., Stuve O., and Williams G.. 1998. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 51: 682–689. PubMed
Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H., et al. . 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39: 285–294. PubMed
Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., Hartung H., Seeldrayers P., Sorensen P. S., Rovaris M., et al. . 2001. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 357: 1576–1582. PubMed
Hartung H. P. 2005. Early treatment and dose optimisation BENEFIT and BEYOND. J. Neurol. 252(Suppl 3): iii44–iii50. PubMed
Jacobs L. D., Beck R. W., Simon J. H., Kinkel R. P., Brownscheidle C. M., Murray T. J., Simonian N. A., Slasor P. J., and Sandrock A. W.. 2000. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343: 898–904. PubMed
Rudick R. A., Fisher E., Lee J. C., Simon J., and Jacobs L.. 1999. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 53: 1698–1704. PubMed
Benedict R. H., Bakshi R., Simon J. H., Priore R., Miller C., and Munschauer F.. 2002. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J. Neuropsychiatry Clin. Neurosci. 14: 44–51. PubMed
Benedict R. H., Weinstock-Guttman B., Fishman I., Sharma J., Tjoa C. W., and Bakshi R.. 2004. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch. Neurol. 61: 226–230. PubMed
Bakshi R., Czarnecki D., Shaikh Z. A., Priore R. L., Janardhan V., Kaliszky Z., and Kinkel P. R.. 2000. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 11: 1153–1158. PubMed
Stone L. A., Frank J. A., Albert P. S., Bash C. N., Calabresi P. A., Maloni H., and McFarland H. F.. 1997. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology. 49: 862–869. PubMed
1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology. 47: 889–894. PubMed
PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. 2001. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 56: 1628–1636. PubMed
Filippini G., Munari L., Incorvaia B., Ebers G. C., Polman C., D’Amico R., and Rice G. P.. 2003. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 361: 545–552. PubMed
Sorensen P. S., Ross C., Clemmesen K. M., Bendtzen K., Frederiksen J. L., Jensen K., Kristensen O., Petersen T., Rasmussen S., Ravnborg M., et al. . 2003. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 362: 1184–1191. PubMed
Novick D., Cohen B., and Rubinstein M.. 1994. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell. 77: 391–400. PubMed
Colamonici O., Yan H., Domanski P., Handa R., Smalley D., Mullersman J., Witte M., Krishnan K., and Krolewski J.. 1994. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase. Mol. Cell. Biol. 14: 8133–8142. PubMed PMC
Santos R., Weinstock-Guttman B., Tamano-Blanco M., Badgett D., Zivadinov R., Justinger T., Munschauer F. III, and Ramanathan M.. 2006. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J. Neuroimmunol. 176: 125–133. PubMed
Bertolotto A., Sala A., Malucchi S., Marnetto F., Caldano M., Di Sapio A., Capobianco M., and Gilli F.. 2004. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiatry. 75: 1294–1299. PubMed PMC
Pachner A. R. 1997. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology. 49: 647–650. PubMed
Blanc M., Hsieh W. Y., Robertson K. A., Watterson S., Shui G., Lacaze P., Khondoker M., Dickinson P., Sing G., Rodriguez-Martin S., et al. . 2011. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol. 9: e1000598. PubMed PMC
Browne R. W., Weinstock-Guttman B., Horakova D., Zivadinov R., Bodziak M. L., Tamano-Blanco M., Badgett D., Tyblova M., Vaneckova M., Seidl Z., et al. . 2014. Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry. 85: 859–864. PubMed
Weinstock-Guttman B., Zivadinov R., Horakova D., Havrdova E., Qu J., Shyh G., Lakota E., O’Connor K., Badgett D., Tamano-Blanco M., et al. . 2013. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J. Neurol. Neurosurg. Psychiatry. 84: 1186–1191. PubMed
Tettey P., Simpson S. Jr., Taylor B., Blizzard L., Ponsonby A. L., Dwyer T., Kostner K., and van der Mei I.. 2014. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult. Scler. 20: 1737–1744. PubMed
Tettey P., Simpson S. Jr., Taylor B., Blizzard L., Ponsonby A. L., Dwyer T., Kostner K., and van der Mei I.. 2014. Adverse lipid profile is not associated with relapse risk in MS: results from an observational cohort study. J. Neurol. Sci. 340: 230–232. PubMed
Tettey P., Simpson S. Jr., Taylor B. V., and van der Mei I. A.. 2014. Vascular comorbidities in the onset and progression of multiple sclerosis. J. Neurol. Sci. 347: 23–33. PubMed
Horakova D., Zivadinov R., Weinstock-Guttman B., Havrdova E., Qu J., Tamano-Blanco M., Badgett D., Tyblova M., Bergsland N., Hussein S., et al. . 2013. Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One. 8: e53996. PubMed PMC
Friedewald W. T., Levy R. I., and Fredrickson D. S.. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499–502. PubMed
Uher T., Horakova D., Bergsland N., Tyblova M., Ramasamy D. P., Seidl Z., Vaneckova M., Krasensky J., Havrdova E., and Zivadinov R.. 2014. MRI correlates of disability progression in patients with CIS over 48 months. Neuroimage Clin. 6: 312–319. PubMed PMC
Uher T., Horakova D., Kalincik T., Bergsland N., Tyblova M., Ramasamy D. P., Seidl Z., Vaneckova M., Krasensky J., Havrdova E. ,et al. . 2015. Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a. Eur. J. Neurol. 22: 1113–1123. PubMed
Weinstock-Guttman B., Horakova D., Zivadinov R., Tamano-Blanco M., Badgett D., Tyblova M., Vaneckova M., Seidl Z., Krasensky J., Bergsland N., et al. . 2013. Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. J. Neuroimmunol. 263: 121–127. PubMed
Chataway J., Schuerer N., Alsanousi A., Chan D., MacManus D., Hunter K., Anderson V., Bangham C. R., Clegg S., Nielsen C., et al. . 2014. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 383: 2213–2221. PubMed
Marrie R. A., Rudick R., Horwitz R., Cutter G., Tyry T., Campagnolo D., and Vollmer T.. 2010. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 74: 1041–1047. PubMed PMC
Zivadinov R., Marr K., Cutter G., Ramanathan M., Benedict R. H., Kennedy C., Elfadil M., Yeh A. E., Reuther J., Brooks C., et al. . 2011. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology. 77: 138–144. PubMed
Morra V. B., Coppola G., Orefice G., De Michele G., Vacca G., Filla A., and Bonavita V.. 2004. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients. Neurology. 62: 829–830. PubMed
Dixon R. M., Borden E. C., Keim N. L., Anderson S., Spennetta T. L., Tormey D. C., and Shrago E.. 1984. Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons. Metabolism. 33: 400–404. PubMed
Shinohara E., Yamashita S., Kihara S., Hirano K., Ishigami M., Arai T., Nozaki S., Kameda-Takemura K., Kawata S., and Matsuzawa Y.. 1997. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology. 25: 1502–1506. PubMed
Chen Y., Wang S., Yi Z., Tian H., Aliyari R., Li Y., Chen G., Liu P., Zhong J., Chen X., et al. . 2014. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci. Rep. 4: 7242. PubMed PMC